N-803 Clinical Trials
6 recruitingDrug
Phase 25Phase 12Phase 31
Showing 1–6 of 6 trials
Recruiting
Phase 1Phase 2
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
Metastatic Colorectal Cancer
National Cancer Institute (NCI)60 enrolled1 locationNCT06149481
Recruiting
Phase 3
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
NSCLC Stage IV
ImmunityBio, Inc.507 enrolled19 locationsNCT06745908
Recruiting
Phase 1Phase 2
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
Endometrial CancerEndometrial CarcinomaCancer of Endometrium+1 more
National Cancer Institute (NCI)60 enrolled1 locationNCT06253494
Recruiting
Phase 2
Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma
Stage II Squamous Cell Carcinoma of the Head and NeckStage III Squamous Cell Carcinoma of the Head and NeckStage IV Squamous Cell Carcinoma of the Head and Neck
National Cancer Institute (NCI)40 enrolled1 locationNCT06161545
Recruiting
Phase 2
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
Glioblastoma
ImmunityBio, Inc.34 enrolled4 locationsNCT06061809
Recruiting
Phase 2
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer
ImmunityBio, Inc.20 enrolled2 locationsNCT06710288